CA-VELODYNE-LIDAR,-INC.
3.9.2021 06:02:10 CEST | Business Wire | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) will demonstrate its innovative lidar technologies at IAA Mobility (Hall B3, Booth A75) from Sept. 7 to 12 in Munich. Velodyne will display its technology leadership and product breadth in lidar sensors and software. Velodyne’s solutions power autonomous applications that advance safe, sustainable and accessible mobility, infrastructure and security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005892/en/
Velodyne is hosting a press event at its IAA Mobility booth on Sept. 6 at 1:15 to 1:30 p.m. Velodyne executives will highlight how Velodyne´s solutions deliver the performance, range and reliability to power customers’ next-generation infrastructure and mobile applications. They will also discuss Velodyne’s portfolio of compact, solid-state sensors, which are embeddable for sleek, stylish integration into vehicles and robotics applications.
“At IAA Mobility, we will show how Velodyne’s sensors and software meet a wide range of customer needs to power safe mobility and smart city infrastructure globally,” said Erich Smidt, Vice President of Europe, Velodyne Lidar. “We will also have partners in our stand that are at the forefront in bringing to market the future of autonomous solutions. NI and Seoul Robotics are both recognized leaders in delivering high-quality solutions with the goal of improving people’s lives and increasing safety in our communities.”
Partners Showcase Lidar-Based Solutions
NI , developer of automated test and automated measurement systems, will co-exhibit at the Velodyne booth. NI will show simulations optimized for Velodyne’s lidar sensors that can be used in developing and testing advanced driver assistance systems (ADAS) and autonomous vehicle (AV) capabilities. NI simulation solutions make it easier to integrate Velodyne’s sensors into vehicle solutions, providing faster time to market and improving vehicle safety. NI will demonstrate how its monoDrive AV simulation software is using Velodyne’s lidar technology to create digital twins and is providing validated physics-based sensor models for Velodyne lidar sensors.
“Our ADAS and lidar simulation capabilities support faster system development and deployment of ADAS and AV solutions that use Velodyne’s sensors. The NI monoDrive Real-to-Virtual technology provides an end-to-end solution for collecting real-world data from cameras, lidars and GNSS systems to create high-fidelity digital twins that help to accelerate ADAS and AV development,” said Jeff Phillips, Director of Marketing for NI’s Transportation Business Unit. “The combination of Velodyne’s high-performance sensors and our simulation and validation capabilities allows developers to test and validate solutions in a massively scalable variety of conditions before they reach the road.”
Seoul Robotics , an Automated with Velodyne partner, will demonstrate at the Velodyne booth its AI perception engine for Velodyne’s lidar sensors which provides real-time object detection, classification, tracking and prediction for autonomous systems. The AI engine can power self-driving cars as well as smart city applications and advanced parameter monitoring systems for facilities. Seoul Robotics’ SENSR™ perception software includes an AI engine that is fully optimized to utilize Velodyne’s portfolio of lidar sensors, including the Puck™ , Ultra Puck™ and Alpha Prime™ .
Velodyne Highlights High Performance Sensors and Software
Among the Velodyne products showcased at IAA Mobility are:
Velarray H800 , a solid-state lidar sensor architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA). With combined long-range perception and a broad field of view, the sensor is designed for safe navigation and collision avoidance in ADAS and autonomous mobility applications. It can enable advanced driver assistance features such as Adaptive Cruise Control (ACC), Lane Keep Assist (LKA) and Pedestrian Automatic Emergency Braking (PAEB). The Velarray H800’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior.
Velarray M1600 , an innovative solid-state lidar sensor designed to serve mobile robotic applications. The sensor is built using Velodyne’s MLA and provides outstanding near-field perception for safe navigation. The Velarray M1600 enables touchless mobile and last-mile delivery robots to operate autonomously and safely, without human intervention. This durable and compact sensor can be deployed in a wide variety of environments and weather conditions allowing nearly 365-day, 24/7 usage.
Velabit™ , Velodyne’s smallest sensor, which brings new levels of versatility and affordability to 3D lidar perception. This compact, mid-range lidar sensor is highly configurable for specialized use cases and can be embedded almost anywhere within vehicles, robots, unmanned aerial vehicles (UAVs) and infrastructure. The solid-state Velabit advances Velodyne’s mission to make high-quality 3D lidar sensors readily accessible to everyone.
Vella™ , Velodyne’s breakthrough ADAS software based on the directional view Velarray sensor. Vastly superior to existing approaches that utilize camera+radar, Vella will revolutionize advanced driver assistance functionalities currently on the market, including ACC, LKA and PAEB. The Vella Development Kit (VDK) enables companies to utilize the advanced capabilities of Vella software in their autonomous solutions. VDK helps companies use their development resources more efficiently by reducing the time and effort required to integrate 3D lidar sensors into applications.
About Velodyne Lidar
Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .
Forward Looking Statements
This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005892/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
